A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

The UK DRI has announced an international research study to assess whether a finger-prick blood test could help diagnose ...

Lipocine has completed the enrolment and participant dosing in its Phase III clinical trial investigating LPCN 1154 to treat ...

Tanabe Pharma America, a subsidiary of the Tanabe Pharma Corporation, is not the only company developing drugs for EPP and ...

Genespire is looking to take its single-dose gene therapy, GENE202, to the clinic by the end of 2026, where it will be ...

Adalyon’s CEO, Ulrik Zeuthen, notes that speech-based biomarkers can be used across several applications to optimise trial ...

BBH has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials.

Genmab has announced topline results from the Phase III EPCORE DLBCL-1 trial, highlighting improved PFS for its subcutaneous ...

William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.

Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.

Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap its development.